Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
- Primary completion Nov 22, 2026Sponsor estimatePhase 1NCT07820891A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395BeOne Medicines · Healthy Adult ParticipantsRecruitingONCLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 23, 2026Sponsor estimatePhase 1NCT06545331Study of XB010 in Subjects With Solid TumorsExelixis · Locally Advanced or Metastatic Solid TumorsRecruitingEXELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 24, 2026Sponsor estimatePhase 1/Phase 2NCT06267729Study of AZD0754 in Participants With Metastatic Prostate CancerAstraZeneca · Metastatic Prostate CancerRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT06063850AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe EpilepsyUniQure Biopharma B.V. · Mesial Temporal Lobe EpilepsyRecruitingQURELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT06840119Phase 1/2 Study of IMC-R117C in Selected Advanced CancersImmunocore Ltd · CancerRecruitingIMCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1NCT07005713A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg...BeOne Medicines · Chronic Spontaneous UrticariaRecruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1NCT07946575A Study of the Potential Pharmacokinetic Interaction Between Quinidine Sulfate and Nalbuphine Extended-Release Tablets (NAL ER) in...Trevi Therapeutics · Healthy ParticipantsRecruitingTRVILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 1, 2026Sponsor estimatePhase 1NCT06680037A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune DisordersTG Therapeutics, Inc. · B-cell Mediated Autoimmune DisordersRecruitingTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 1NCT06891287An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.RANI Therapeutics · ObesityRecruitingRANILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 3, 2026Sponsor estimatePhase 1NCT07464314A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in AdultsGlaxoSmithKline · Influenza, Human+COVID-19RecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 4, 2026Sponsor estimatePhase 1NCT07231991A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver FunctionPfizer · Healthy ParticipantsRecruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 5, 2026Sponsor estimatePhase 1NCT07777133A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy...Bristol-Myers Squibb · Healthy Female ParticipantsRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 8, 2026Sponsor estimatePhase 1NCT07290283A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy ParticipantsAstraZeneca · Healthy ParticipantsRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 8, 2026Sponsor estimatePhase 1NCT07465653A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection FractionNovartis Pharmaceuticals · Heart Failure With Reduced Ejection FractionRecruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 8, 2026Sponsor estimatePhase 1NCT07721402A Study to Learn About How Different Forms of Study Medicine Prifetrastat Are Taken Up Into the Blood in Healthy AdultsPfizer · Healthy ParticipantRecruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 9, 2026Sponsor estimatePhase 1NCT07049575Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaIncyte Corporation · Hidradenitis SuppurativaRecruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 9, 2026Sponsor estimatePhase 1NCT07769489Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and AcceptanceNovo Nordisk A/S · Healthy ParticipantsRecruitingNVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 13, 2026Sponsor estimatePhase 1NCT07225816Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in...Novo Nordisk A/S · ObesityRecruitingNVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2026Sponsor estimatePhase 1NCT07763418A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal...Bristol-Myers Squibb · Kidney Failure, ChronicRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 1/Phase 2NCT04585750The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PMV Pharmaceuticals, Inc · Advanced Solid TumorRecruitingPMVPLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 1NCT07223125A Study of JNJ-89862175 for Treatment of Advanced Solid TumorsJanssen Research & Development, LLC · Advanced-stage Solid TumorsRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 1NCT07868926Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral DoseVertex Pharmaceuticals Incorporated · Autosomal Dominant Polycystic Kidney Disease (ADPKD)RecruitingVRTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 16, 2026Sponsor estimatePhase 1NCT06655870A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy ParticipantsModernaTX, Inc. · Healthy ParticipantsRecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2026Sponsor estimatePhase 1NCT07226817A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult ParticipantsBristol-Myers Squibb · Healthy VolunteersRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2026Sponsor estimatePhase 1NCT07444294A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy AdultsScholar Rock, Inc. · HealthyRecruitingSRRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 1 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.